Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI in Haploidentical Donor HCT for Hematologic Malignancies
NCT03849651Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jan 2019
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD45RA depleted donor lymphocyte infusion and blinatumomab in hematologic malignancy, sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Effective Dose for Prophylactic CD45RA-depleted DLI and One-year Event Free Survival at 1 year. Started Jan 2019; status: active, not recruiting.
02
Drugs
CD45RA depleted donor lymphocyte infusionblinatumomab
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03849651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849651.